Do preclinical studies suggest that CD99 is a potential therapeutic target in acute myeloid leukemia and the myelodysplastic syndromes?

Montreh Tavakkoli, Stephen S. Chung, Christopher Y. Park

Research output: Contribution to journalEditorial

2 Citations (Scopus)

Abstract

Introduction: Acute myeloid leukemia (AML) and the myelodysplastic syndromes (MDS) are clonal hematopoietic neoplasms that arise from leukemia stem cells (LSCs) and hematopoietic stem cells (HSCs), respectively. Standard chemotherapy can efficiently eliminate the bulk of neoplastic cells, however, LSCs and MDS HSCs are relatively resistant to these therapies and can reinitiate and maintain disease. CD99 is a 32-kDa transmembrane polypeptide that is highly expressed on disease stem cells in the vast majority of AML and MDS. Areas covered: In this editorial, we focus on the current literature surrounding the identification of CD99 as a marker of MDS and AML stem cells and preclinical studies revealing the therapeutic efficacy of targeting CD99 in these diseases. Expert opinion/commentary: Cytotoxic CD99 monoclonal antibodies represent promising stem cell-directed therapies that have the potential to markedly improve clinical outcomes for these difficult-to-treat hematologic malignancies.

Original languageEnglish (US)
Pages (from-to)381-383
Number of pages3
JournalExpert Opinion on Therapeutic Targets
Volume22
Issue number5
DOIs
StatePublished - May 4 2018
Externally publishedYes

Fingerprint

Myelodysplastic Syndromes
Stem cells
Acute Myeloid Leukemia
Stem Cells
Hematologic Neoplasms
Hematopoietic Stem Cells
Leukemia
Myeloid Progenitor Cells
Expert Testimony
Therapeutics
Cell- and Tissue-Based Therapy
Monoclonal Antibodies
Chemotherapy
Drug Therapy
Peptides

Keywords

  • AML
  • antibody
  • cancer stem cells
  • CD99
  • CSC
  • HSC
  • immunotherapy
  • leukemia
  • leukemia stem cell
  • LSC
  • MDS
  • myeloid
  • stem cell
  • stem cell-directed therapy
  • therapeutic target

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Do preclinical studies suggest that CD99 is a potential therapeutic target in acute myeloid leukemia and the myelodysplastic syndromes? / Tavakkoli, Montreh; Chung, Stephen S.; Park, Christopher Y.

In: Expert Opinion on Therapeutic Targets, Vol. 22, No. 5, 04.05.2018, p. 381-383.

Research output: Contribution to journalEditorial

@article{a991e103e8f544788e6d4db7abed674c,
title = "Do preclinical studies suggest that CD99 is a potential therapeutic target in acute myeloid leukemia and the myelodysplastic syndromes?",
abstract = "Introduction: Acute myeloid leukemia (AML) and the myelodysplastic syndromes (MDS) are clonal hematopoietic neoplasms that arise from leukemia stem cells (LSCs) and hematopoietic stem cells (HSCs), respectively. Standard chemotherapy can efficiently eliminate the bulk of neoplastic cells, however, LSCs and MDS HSCs are relatively resistant to these therapies and can reinitiate and maintain disease. CD99 is a 32-kDa transmembrane polypeptide that is highly expressed on disease stem cells in the vast majority of AML and MDS. Areas covered: In this editorial, we focus on the current literature surrounding the identification of CD99 as a marker of MDS and AML stem cells and preclinical studies revealing the therapeutic efficacy of targeting CD99 in these diseases. Expert opinion/commentary: Cytotoxic CD99 monoclonal antibodies represent promising stem cell-directed therapies that have the potential to markedly improve clinical outcomes for these difficult-to-treat hematologic malignancies.",
keywords = "AML, antibody, cancer stem cells, CD99, CSC, HSC, immunotherapy, leukemia, leukemia stem cell, LSC, MDS, myeloid, stem cell, stem cell-directed therapy, therapeutic target",
author = "Montreh Tavakkoli and Chung, {Stephen S.} and Park, {Christopher Y.}",
year = "2018",
month = "5",
day = "4",
doi = "10.1080/14728222.2018.1464140",
language = "English (US)",
volume = "22",
pages = "381--383",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Do preclinical studies suggest that CD99 is a potential therapeutic target in acute myeloid leukemia and the myelodysplastic syndromes?

AU - Tavakkoli, Montreh

AU - Chung, Stephen S.

AU - Park, Christopher Y.

PY - 2018/5/4

Y1 - 2018/5/4

N2 - Introduction: Acute myeloid leukemia (AML) and the myelodysplastic syndromes (MDS) are clonal hematopoietic neoplasms that arise from leukemia stem cells (LSCs) and hematopoietic stem cells (HSCs), respectively. Standard chemotherapy can efficiently eliminate the bulk of neoplastic cells, however, LSCs and MDS HSCs are relatively resistant to these therapies and can reinitiate and maintain disease. CD99 is a 32-kDa transmembrane polypeptide that is highly expressed on disease stem cells in the vast majority of AML and MDS. Areas covered: In this editorial, we focus on the current literature surrounding the identification of CD99 as a marker of MDS and AML stem cells and preclinical studies revealing the therapeutic efficacy of targeting CD99 in these diseases. Expert opinion/commentary: Cytotoxic CD99 monoclonal antibodies represent promising stem cell-directed therapies that have the potential to markedly improve clinical outcomes for these difficult-to-treat hematologic malignancies.

AB - Introduction: Acute myeloid leukemia (AML) and the myelodysplastic syndromes (MDS) are clonal hematopoietic neoplasms that arise from leukemia stem cells (LSCs) and hematopoietic stem cells (HSCs), respectively. Standard chemotherapy can efficiently eliminate the bulk of neoplastic cells, however, LSCs and MDS HSCs are relatively resistant to these therapies and can reinitiate and maintain disease. CD99 is a 32-kDa transmembrane polypeptide that is highly expressed on disease stem cells in the vast majority of AML and MDS. Areas covered: In this editorial, we focus on the current literature surrounding the identification of CD99 as a marker of MDS and AML stem cells and preclinical studies revealing the therapeutic efficacy of targeting CD99 in these diseases. Expert opinion/commentary: Cytotoxic CD99 monoclonal antibodies represent promising stem cell-directed therapies that have the potential to markedly improve clinical outcomes for these difficult-to-treat hematologic malignancies.

KW - AML

KW - antibody

KW - cancer stem cells

KW - CD99

KW - CSC

KW - HSC

KW - immunotherapy

KW - leukemia

KW - leukemia stem cell

KW - LSC

KW - MDS

KW - myeloid

KW - stem cell

KW - stem cell-directed therapy

KW - therapeutic target

UR - http://www.scopus.com/inward/record.url?scp=85045767405&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045767405&partnerID=8YFLogxK

U2 - 10.1080/14728222.2018.1464140

DO - 10.1080/14728222.2018.1464140

M3 - Editorial

C2 - 29637789

AN - SCOPUS:85045767405

VL - 22

SP - 381

EP - 383

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - 5

ER -